Sarepta Therapeutics Q3 2026: Revenue Beat Buried by a $62 Million Charge

As seen on the 24/7 Wall St. homepage on November 5, 2026.

SRPT Sarepta Therapeutics
Q3 2026
EPS
$0.13
est $0.36 -63.6%
Revenue
$381M
est $350M +8.9%

A $62 million Catalent take-or-pay charge separates a revenue beat from an EPS miss, and management still raised the low end of full-year product revenue guidance to $1.25 billion to $1.3 billion. ELEVIDYS volume shrank under its ambulatory-only label while the PMO exon-skipping franchise carried the quarter. DM1 and FSHD dose data land before year end.

Continue ReadingShow less

Sarepta's third quarter of 2026 presented investors with a split verdict: revenue of $381.35 million came in nearly 9% above the $350.10 million consensus, yet adjusted non-GAAP EPS of $0.13 came in well below the $0.36 estimate, missing expectations. The gap between those two outcomes traces almost entirely to a $62 million Catalent take-or-pay charge that landed in cost of sales and carved deeply into what would otherwise have been a cleaner profit picture.

The PMO exon-skipping franchise, which includes EXONDYS 51, VYONDYS 53, and AMONDYS 45, generated $240.3 million in net product revenue and was the workhorse of the quarter. ELEVIDYS, the gene therapy for Duchenne muscular dystrophy, contributed $83.5 million, a figure constrained by the therapy's label being narrowed to ambulatory patients. Management said Q4 ELEVIDYS revenue is expected to trend in line with Q3, flagging the inherent variability of a one-time gene therapy.

Despite the EPS shortfall, management moved guidance in a constructive direction. The low end of full-year net product revenue guidance was raised by $50 million, putting the range at $1.25 billion to $1.3 billion. At the same time, the high end of combined non-GAAP R&D and SG&A expense guidance was trimmed by $25 million, to a range of $800 million to $825 million, signaling some commitment to cost discipline.

Sponsored

The quarter is also the first full report under CEO Michael Severino, who acknowledged the company has work to do and said he wants Sarepta to be measured by execution. His more forward-looking remarks centered on the pipeline: multiple ascending dose data for SRP-1003, targeting myotonic dystrophy type 1, and SRP-1001, targeting facioscapulohumeral muscular dystrophy, are both expected before year-end 2026. Sarepta said it is already preparing both programs for potential late-stage development under accelerated and traditional approval pathways.

What investors will be weighing in the near term is whether the DM1 and FSHD datasets, when they arrive, show the depth of knockdown and downstream biological effects the company believes its platform can achieve. Severino described those readouts as important opportunities for the platform, and the company said it expects its balance sheet and commercial cash flows to fund late-stage development without needing to raise capital.

Mentioned: SRPT